Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells

[1]  M. Milella,et al.  Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree: series of 106 consecutive patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Kang,et al.  Expression of MAP kinases and connexins in the differentiation of rat mammary epithelial cells. , 2006, The Journal of veterinary medical science.

[3]  T. Chou,et al.  5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer , 2005, Journal of Gastrointestinal Surgery.

[4]  M. Bettmann,et al.  Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma , 2005, Annals of Surgical Oncology.

[5]  M. Tempero,et al.  Systemic therapy for pancreatic cancer. , 2005, Seminars in radiation oncology.

[6]  S. Di Cosimo,et al.  Fixed dose‐rate gemcitabine infusion as first‐line treatment for advanced‐stage carcinoma of the pancreas and biliary tree , 2005, Cancer.

[7]  H. Okano,et al.  Characterization of ABC transporter ABCB1 expressed in human neural stem/progenitor cells , 2005, FEBS letters.

[8]  A. Mitra,et al.  Role of efflux pumps and metabolising enzymes in drug delivery , 2005, Expert opinion on drug delivery.

[9]  E. Giovannetti,et al.  Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma , 2005, British Journal of Cancer.

[10]  H. Okano,et al.  Functional expression of ABCG2 transporter in human neural stem/progenitor cells , 2005, Neuroscience Research.

[11]  M. Gilbert,et al.  Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. , 2005, Neuro-oncology.

[12]  H. Hess-Stumpp.  Histone deacetylase inhibitors and cancer: from cell biology to the clinic. , 2005, European journal of cell biology.

[13]  K. Bhalla,et al.  Histone deacetylase inhibitors in myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[14]  T. Ekström,et al.  HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. , 2004, Biochemical and biophysical research communications.

[15]  Qiang Yu,et al.  Sodium 4‐phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway , 2004, Journal of cellular biochemistry.

[16]  Young-ho Kim,et al.  Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. , 2004, Carcinogenesis.

[17]  C. Pilarsky,et al.  Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. , 2004, Neoplasia.

[18]  T. Ekström,et al.  Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. , 2004, European journal of cancer.

[19]  J. Rutka,et al.  Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization , 2004, Oncogene.

[20]  T. Okumura,et al.  Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. , 2004, Biochemical and biophysical research communications.

[21]  C. Chow,et al.  Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells , 2004, Clinical Cancer Research.

[22]  H. Kalthoff,et al.  Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells , 2003, British Journal of Cancer.

[23]  Rork Kuick,et al.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. , 2003, Cancer research.

[24]  M. Löhr,et al.  A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform , 2003, Virchows Archiv.

[25]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.

[26]  T. Ekström,et al.  Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. , 2003, International journal of oncology.

[27]  Tatjana Crnogorac-Jurcevic,et al.  Expression profiling of microdissected pancreatic adenocarcinomas , 2002, Oncogene.

[28]  M. Jung,et al.  Inhibitors of histone deacetylase as new anticancer agents. , 2001, Current medicinal chemistry.

[29]  L. Harrison,et al.  Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3. , 2001, Cancer letters.

[30]  M. Nishiyama,et al.  Histone deacetylase as a new target for cancer chemotherapy , 2001, Cancer Chemotherapy and Pharmacology.

[31]  G. Szakács,et al.  Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia , 2001, British journal of haematology.

[32]  T. Sakai,et al.  Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites , 2000, Oncogene.

[33]  M. Tsao,et al.  Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. , 2000, The American journal of pathology.

[34]  D. Samid,et al.  Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure–function analysis , 1999, Leukemia.

[35]  D. Samid,et al.  Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Lea,et al.  Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. , 1999, Anticancer research.

[37]  C. Allis,et al.  Roles of histone acetyltransferases and deacetylases in gene regulation , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  M. Haymond,et al.  Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. , 1998, American journal of physiology. Endocrinology and metabolism.

[39]  H. Kalthoff,et al.  Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. , 1998, Cancer research.

[40]  P. Zeitlin,et al.  A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. , 1998, American journal of respiratory and critical care medicine.

[41]  T. Tokino,et al.  Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line* , 1997, The Journal of Biological Chemistry.

[42]  C. Naus,et al.  Role of connexin genes in growth control. , 1996, Carcinogenesis.

[43]  M. Tsao,et al.  Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.

[44]  J. Nelson,et al.  Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  A. Hindenburg,et al.  Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. , 1987, Cancer research.

[46]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[47]  Balázs Sarkadi,et al.  The role of ABC transporters in drug resistance, metabolism and toxicity. , 2004, Current drug delivery.

[48]  A. Arlt,et al.  Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. , 2003, Oncogene.

[49]  L. Harrison,et al.  Phenylbutyrate-induced apoptosis is associated with inactivation of NF-κB IN HT-29 colon cancer cells , 2001, Cancer Chemotherapy and Pharmacology.

[50]  T. Sakai,et al.  Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.". , 2000, BioFactors.

[51]  S. Shack,et al.  Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. , 1997, Advances in experimental medicine and biology.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.